Canadian Journal of Anaesthesia

, Volume 39, Issue 9, pp 975–979 | Cite as

Anaesthetic implications of 32% Dextran-70 (Hyskon®) during hysteroscopy: hysteroscopy syndrome

  • Devanand Mangar
Brief Reviews


This review describes the properties and side effects of Hyskon® and the implications for the patient and anaesthetist during hysteroscopy. The amount of Hyskon® absorbed is dependent on the injection pressure, the extent of tissue trauma, the seal of the hysteroscope around the cervix, and the duration of infusion. The mechanism of pulmonary oedema after absorbtion of Hyskon® is fluid overload, and not injury to pulmonary capillary endothelium. The haematological effects are primarily due to haemodilution. However, case reports suggest that Dextran 70 may cause a syndrome resembling disseminated intravascular coagulation. The allergic response to Hyskon® consists of both an anaphylactic and an anaphylactoid component. It is recommended that hysteroscopy with Hyskon® be limited to 45 min, and that all possible measures be taken to minimize tissue trauma and bleeding. The volume of Hyskon® should be limited to less than 500 ml, since pulmonary oedema and coagulopathy have been described with even lesser amounts. The cumulative volume of Hyskon® should be monitored frequently and the patient should be closely monitored for signs of impending pulmonary oedema.

Key words

complications: pulmonary oedema surgery: gynaecological, hysteroscopy syndromes: hysteroscopy 


Cet article décrit les propriétés et les effets secondaires de l’Hyskon® et les implications pour le patient et l’anesthesiste pendant l’hystéroscopie. La quantité d’Hyskon absorbée dépend de la pression dinjection, de l’extension du traumatisme tissulaire, de l’étanchéité de l’hystéroscope inséré dans le col et de la durée de la perfusion. Le mécanisme de Voedème pulmonaire après la résorbtion d’Hyskon est une surcharge liquidienne et non une lésion endothéliale des capillaires pulmonaires. Les effets hématologiques sont d’abord dus à l’ hémodilution bien que des rapports de cas suggèrent que le dextran 70 peut causer d’emblée une coagulation intravasculaire disséminée. La réponse allergique à l’Hyskon comporte à la fois un versant anaphylactique et anaphylactoïde. On recommande que l’hysteroscopie à l’Hyskon soit limitée à 45 minutes et que soient pris tous les moyens possibles pour diminuer le traumatisme tissulaire et le saignement. Le volume d’Hyskon doit être limité à moins de 500 ml puisque l’oedème pulmonaire et la coagulopathie ont été même décrits pour des quantités moindres. La quantité perfusée d’Hyskon devrait être régulière comptabilisée et le patient devrait être étroitement monitorisé quant aux signes précurseurs d’oedème pulmonaire.


  1. 1.
    Lavy G, Diamond MP, Shapiro B, DeCherney AH. A new device to facilitate intrauterine instillation of dextran 70 for hysteroscopy. Obstet Gynecol 1987; 70: 955–7.PubMedGoogle Scholar
  2. 2.
    Kaplan AI, Sabin S. Dextran 40: Another cause of druginduced noncardiogenic pulmonary edema. Chest 1975; 68: 376–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Mangar D, Gerson JI, Constantine RM, Lenzi V. Pulmonary edema and coagulopathy due to Hyskon® (32% dextran-70) administration. Anesth Analg 1989; 68: 686–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Schinagl EF. Hyskon® (32% Dextran 70), hysteroscopic surgery and pulmonary edema (Letter). Anesth Analg 1990; 70: 222–3.CrossRefGoogle Scholar
  5. 5.
    Zbella EA, Moise J, Carsan SA. Noncardiogenic pulmonary edema secondary to intrauterine instillation of 32% dextran-70. Fertil Steril 1985; 43: 479–80.PubMedGoogle Scholar
  6. 6.
    Leake JF, Murphy AA, Zacur HA. Noncardiogenic pulmonary edema: a complication of operative hysteroscopy. Fertil Steril 1987; 48: 497–9.PubMedGoogle Scholar
  7. 7.
    Lukacsko P. Noncardiogenic pulmonary edema secondary to intrauterine instillation of 32% dextran-70 (Letter). Fertil Steril 1985; 44: 560–1.PubMedGoogle Scholar
  8. 8.
    Jedeikin R, Olsfanger D, Kessler I. Disseminated intravascular coagulopathy and adult respiratory syndrome: life-threatening complications of hysteroscopy. Am J Obstet Gynecol 1990; 162: 44–5.PubMedGoogle Scholar
  9. 9.
    Golan A, Siedner M, Bahar M, Ron-El R, Herman A, Caspi E. High-output left ventricular failure after dextran use in an operative hysteroscopy. Fertil Steril 1990; 54: 939–41.PubMedGoogle Scholar
  10. 10.
    Choban MJ, Kalhan SB, Anderson RJ, Collins R. Pulmonary edema and coagulopathy following intrauterine instillation of 32% Dextran-70 (Hyskon). J Clin Anesth 1991; 3: 317–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Pantaleoni D. On endoscopic examination of the cavity of the womb. The Medical Press and Circular 1869; 8: 26–27.Google Scholar
  12. 12.
    Baggish MS. Distending media for panoramin hysteroscopy. In: Baggish MS, Barbot J, Valle RRF. (Eds.). Diagnostic and Operative Hysteroscopy: A Text and Atlas, Chicago: Yearbook Medical Publishers 1989; 89–93.Google Scholar
  13. 13.
    Edstron K, Ferstrom I. The diagnostic possibilities of a modified hysteroscopic technique. Acta Obstet Gynecol Scand 1970; 49: 327–30.CrossRefGoogle Scholar
  14. 14.
    Neuwirth RS, Amin HK. Excision of submucous fibroids with hysteroscopic control. Am J Obstet Gynecol 1976; 126: 95–9.PubMedGoogle Scholar
  15. 15.
    DeCherney A, Polan ML Hysteroscopic management of intrauterine lesions and intractable bleeding. Obstet Gynecol 1983; 61: 392–7.Google Scholar
  16. 16.
    Mangar D, Gerson JI, Baggish MS, Camporesi EM. Serum levels of Hyskon® during hysteroscopic procedures. Anesth Analg 1991; 173: 186–9.Google Scholar
  17. 17.
    Frand UI, Shim CS, Williams H. Methadone-induced pulmonary edema. Ann Intern Med 1972; 76: 975–9.PubMedGoogle Scholar
  18. 18.
    Steinberg AD, Karliner JS. The clinical spectrum of heroin pulmonary edema. Arch Intern Med 1968; 122: 122–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Hrnicek G, Skeleton J, Miller WC. Pulmonary edema and salicylate intoxication. JAMA 1974; 230: 866–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Data JL, Nies AS. Drugs five years later: Dextran 40. Ann Intern Med 1974; 81: 500–4.PubMedGoogle Scholar
  21. 21.
    Moran M, Kapsner C. Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med 1987; 317: 150–3.PubMedGoogle Scholar
  22. 22.
    Atik M. Dextran 40 and dextran 70: a review. Arch Surg 1967: 94: 664–72.PubMedGoogle Scholar
  23. 23.
    Adoni A, Adatto-Levy R, Mogle P, Palti Z. Postoperative pleural effusion caused by dextran. Int J Gynaecol Obstet 1980; 18: 243–4.PubMedGoogle Scholar
  24. 24.
    Tulandi T. Transient edema after intraperitoneal instillation of 32% dextran 70. A report of five cases. J Reprod Med 1987; 32: 472–4.PubMedGoogle Scholar
  25. 25.
    Tulandi T, Hilton J. Effects of intraperitoneal instillation of 32% dextran 70 on blood coagulation and serum electrolytes. J Reprod Med 1985; 30: 431–4.PubMedGoogle Scholar
  26. 26.
    Floral PA, Svensson J, Ljungstrom K-G. Effects of desmopressin and dextran on coagulation and fibrinolysis in healthy volunteers. Throm Res 1991; 62: 355–64.CrossRefGoogle Scholar
  27. 27.
    Klotz U, Kroemer H. Clinical pharmacokinetics considerations in the use of plasma expanders. Clin Pharmacokinet 1987; 12: 123–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Atik M. The use of dextran in surgery: a current evaluation. Surgery 1969; 65: 548–62.PubMedGoogle Scholar
  29. 29.
    Bydeman S, Eliasson R. Effect of dextran on platelets adhesiveness and aggregation. Scan J Clin Lab Invest 1967; 20: 17–23.CrossRefGoogle Scholar
  30. 30.
    Berliner AD, Lackner H. Hemhorragic diathesis after prolonged infusion of low molecular weight dextran. Am J Med Sci 1972; 263: 397–403.PubMedCrossRefGoogle Scholar
  31. 31.
    Morgan TO, Little JM, Evans WA. Renal failure associated with low molecular weight dextran infusion. BMJ 1966; 2: 737–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Mailloux L, Swartz CD, Capizzi R, et al. Acute renal failure after administration of low molecular weight dextran. N Engl J Med 1967; 277: 1113–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Bailey G, Strub RL, Klein RC, Salvaggio J. Dextraninduced anaphylaxis. JAMA 1967; 200: 889–91.PubMedCrossRefGoogle Scholar
  34. 34.
    Paull J. A prospective study of dextran-induced anaphylactoid reaction in 5745 patients. Anaesth Intensive Care 1987; 15: 163–7.PubMedGoogle Scholar
  35. 35.
    Ahmed N, Falcone T, Tulandi T, Houle G. Anaphylactic reaction because of intrauterine 32% dextran-70 instillation. Fertil Steril 1991; 55: 1014–6.PubMedGoogle Scholar
  36. 36.
    Taylor PJ, Cumming D. Hysteroscopy in 100 patients. Fertil Steril 1979; 31: 301–4.PubMedGoogle Scholar
  37. 37.
    Kohen M, Mattikow M, Middleton E Jr,Butsch DW. A study of three untoward reactions to dextran. J Allergy 1970; 46: 309–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Cleary RE, Howard T, diZerega GS. Plasma dextran levels after abdominal instillation of 32% dextran 70: evidence for prolonged intraperitoneal retention. Am J Obstet Gynecol 1985; 152: 78–9.PubMedGoogle Scholar
  39. 39.
    McLucas B. Hyskon® complications in hysteroscopic surgery. Obstet Gynecol Survey 1991; 46: 196–200.CrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 1992

Authors and Affiliations

  • Devanand Mangar
    • 1
  1. 1.Department of AnesthesiologyUniversity of South Florida College of MedicineTampa

Personalised recommendations